Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

658

Participants

Timeline

Start Date

December 20, 2020

Primary Completion Date

December 20, 2021

Study Completion Date

December 20, 2021

Conditions
GastritisDyspepsiaHelicobacter Pylori InfectionGastric CancerPeptic Ulcer
Interventions
DRUG

Esomeprazole

High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet TID plus amoxicillin 500 mg 2 capsules TID

DRUG

Amoxicillin

High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 40mg 1 tablet TID

DRUG

Bismuth

Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 40 mg 1 tablets BID,tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID

DRUG

Esomeprazole

Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet BID plus bismuth 110 mg 2 capsules BID,tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID

DRUG

Tetracycline

Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID,esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID

DRUG

Furazolidone

Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID,esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID

Trial Locations (1)

710032

Xijing Hosipital of Digestive Disease, Xi'an

All Listed Sponsors
lead

Xijing Hospital of Digestive Diseases

OTHER

NCT04678492 - Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy | Biotech Hunter | Biotech Hunter